Watanabe et al. demonstrated in KK-Ay mice, a model for obesity and T2D, that treatment with CA lowered plasma TGs, hepatic TG accumulation, and very-low-density lipoprotein (VLDL) secretion from the liver, which was attributed to the induction of the FXR-SHP axis [72]. The gene discussed is NR1H4; the disease is obesity disorder.